51 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
were collected over the COVID-19 pandemic period.
At the AAN meeting, Takeda additionally presented post-hoc analysis data from the Phase 2 ELEKTRA
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
presented by the ongoing COVID-19 pandemic. Additional risks that could cause actual results to differ materially from those in the forward-looking
8-K
EX-99.1
khi 05j425v3a69wcwcy
9 Aug 22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:18am
8-K
EX-99.1
ih7j6ia34debvhjjwr
10 May 22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
8:05am
8-K
EX-99.1
cc3wb04qt3 zqu3w44lw
15 Mar 22
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
8:29am
8-K
EX-99.1
d9fp0jb3ohg5mkw
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
b7tmygcjr98cvao
10 Nov 21
Corporate Highlights and Financial Results
8:38am
8-K
EX-99.1
64agi8
18 Aug 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
rw95ty 4i1uckm
16 Aug 21
Ovid Therapeutics Reports Second Quarter 2021 Financial Results
8:06am
8-K
EX-99.1
sgw56jt
23 Jun 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
q4qa1o1km46nkol
18 May 21
Regulation FD Disclosure
3:11pm